GlassScriptPhysician profile
Vincent M Koike
NPI 1497843213
$2,585.49
in general payments reported to CMS, 2019-2025
18 companies · $82.20 in 2025
The $82.20 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $407 · 2021: $655 · 2022: $542 · 2023: $292 · 2024: $179 · 2025: $82.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $553.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $997.73 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $349.58 | 2021-2024 | |
| Pfizer INC. | $279.48 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.67 | 2019-2022 | |
| Exact Sciences Corporation | $186.21 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $169.37 | 2019-2022 | |
| Glaxosmithkline, LLC. | $86.01 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $52.44 | 2021 | |
| Eisai INC. | $51.39 | 2020 | |
| Janssen Pharmaceuticals, INC | $48.48 | 2022-2023 | Spravato |
| Teva Pharmaceuticals USA, INC. | $38.72 | 2020-2022 | |
| Esperion Therapeutics, INC. | $25.52 | 2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $23.96 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.39 | 2022 | |
| Allergan, INC. | $19.98 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $16.76 | 2023 | Keveyis |
| Medicomp INC | $13.14 | 2023 | Telepatch Cardiac Monitor |
| Currax Pharmaceuticals LLC | $12.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Koike listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.